PT - JOURNAL ARTICLE AU - PHOSP-COVID Collaborative Group AU - Evans, Rachael Andrea AU - McAuley, Hamish AU - Harrison, Ewen M AU - Shikotra, Aarti AU - Singapuri, Amisha AU - Sereno, Marco AU - Elneima, Omer AU - Docherty, Annemarie B AU - Lone, Nazir I AU - Leavy, Olivia C AU - Daines, Luke AU - Baillie, J Kenneth AU - Brown, Jeremy S AU - Chalder, Trudie AU - De Soyza, Anthony AU - Diar Bakerly, Nawar AU - Easom, Nicholas AU - Geddes, John R AU - Greening, Neil J AU - Hart, Nick AU - Heaney, Liam G AU - Heller, Simon AU - Howard, Luke AU - Jacob, Joseph AU - Jenkins, R Gisli AU - Jolley, Caroline AU - Kerr, Steven AU - Kon, Onn M AU - Lewis, Keir AU - Lord, Janet M AU - McCann, Gerry P AU - Neubauer, Stefan AU - Openshaw, Peter JM AU - Pfeffer, Paul AU - Rowland, Matthew AU - Semple, Malcolm G AU - Singh, Sally J AU - Sheikh, Aziz AU - Thomas, David AU - Toshner, Mark AU - Chalmers, James D AU - Ho, Ling-Pei AU - Horsley, Alex AU - Marks, Michael AU - Poinasamy, Krisnah AU - Wain, Louise V AU - Brightling, Christopher E TI - Physical, cognitive and mental health impacts of COVID-19 following hospitalisation – a multi-centre prospective cohort study AID - 10.1101/2021.03.22.21254057 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.22.21254057 4099 - http://medrxiv.org/content/early/2021/03/24/2021.03.22.21254057.short 4100 - http://medrxiv.org/content/early/2021/03/24/2021.03.22.21254057.full AB - Background The impact of COVID-19 on physical and mental health, and employment following hospitalisation is poorly understood.Methods PHOSP-COVID is a multi-centre, UK, observational study of adults discharged from hospital with a clinical diagnosis of COVID-19 involving an assessment between two- and seven-months later including detailed symptom, physiological and biochemical testing. Multivariable logistic regression was performed for patient-perceived recovery with age, sex, ethnicity, body mass index (BMI), co-morbidities, and severity of acute illness as co-variates. Cluster analysis was performed using outcomes for breathlessness, fatigue, mental health, cognition and physical function.Findings We report findings of 1077 patients discharged in 2020, from the assessment undertaken a median 5 [IQR4 to 6] months later: 36% female, mean age 58 [SD 13] years, 69% white ethnicity, 27% mechanical ventilation, and 50% had at least two co-morbidities. At follow-up only 29% felt fully recovered, 20% had a new disability, and 19% experienced a health-related change in occupation. Factors associated with failure to recover were female, middle-age, white ethnicity, two or more co-morbidities, and more severe acute illness. The magnitude of the persistent health burden was substantial and weakly related to acute severity. Four clusters were identified with different severities of mental and physical health impairment: 1) Very severe (17%), 2) Severe (21%), 3) Moderate with cognitive impairment (17%), 4) Mild (46%), with 3%, 7%, 36% and 43% feeling fully recovered, respectively. Persistent systemic inflammation determined by C-reactive protein was related to cluster severity, but not acute illness severity.Interpretation We identified factors related to recovery from a hospital admission with COVID-19 and four different phenotypes relating to the severity of physical, mental, and cognitive health five months later. The implications for clinical care include the potential to stratify care and the need for a pro-active approach with wide-access to COVID-19 holistic clinical services.Funding: UKRI and NIHRCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN10980107Funding StatementPHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19 (grant references: MR/V027859/1 and COV0319). Core funding was provided by NIHR Leicester Biomedical Research Centre to support the PHOSP-COVID coordination team and NIHR Biomedical Research Centres (BRCs), Clinical Research Facilities (CRF) and NIHR Health Protection Research Unit (HPRU) and Translational Research Collaborations (TRCs) network across the country. The institutional funding that supports the outbreak labs that process the PHOSP samples NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) and Liverpool Experimental Cancer Medicine Centre (grant reference: C18616/A25153) RAE* holds a National Institute for Health Research (NIHR) clinician scientist fellowship (CS-2016-16-020). NJG holds a NIHR post-doctoral fellowship (PDF2017-10-052). JJ was supported by a Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z] and by the NIHR University College London Hospital Biomedical Research Centre, UK. LVW was supported by a GSK / British Lung Foundation Chair in Respiratory Research (C17-1) The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care. No form of payment was given to anyone to produce the manuscript. All members of the writing group have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval: Leeds West Research Ethics Committee 20/YH/0225All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, requests for data access and other relevant study materials are available online at www.phosp.org.